Tivozanib - AVEO Oncology/Kyowa Kirin
Alternative Names: ASP-4130; AV-951; AV951 cpd; AVE-951; FOTIVDA; Fotivda; KHK-4951; Kil 8951; KRN-951; Tivopath; Tivozanib hydrochloride monohydrate; UNII-172030934TLatest Information Update: 23 Jul 2024
At a glance
- Originator Kirin Brewery
- Developer Astellas Pharma; AstraZeneca; AVEO Oncology; Bristol-Myers Squibb; EUSA Pharma; Institute Gustave-Roussy; Kyowa Kirin; Northwestern University; Pharmstandard
- Class Antineoplastics; Eye disorder therapies; Isoxazoles; Quinolines; Small molecules; Urea compounds
- Mechanism of Action Protein tyrosine kinase inhibitors; Vascular endothelial growth factor receptor antagonists; Vascular endothelial growth factor receptor-1 antagonists; Vascular endothelial growth factor receptor-2 antagonists; Vascular endothelial growth factor receptor-3 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Marketed Renal cell carcinoma
- Phase II Diabetic macular oedema; Liver cancer; Soft tissue sarcoma; Wet age-related macular degeneration
- Suspended Colorectal cancer; Fallopian tube cancer; Gastrointestinal cancer; Non-small cell lung cancer; Ovarian cancer; Peritoneal cancer; Triple negative breast cancer
- No development reported Solid tumours
Most Recent Events
- 18 Jul 2024 Efficacy and adverse event data from the phase III TIVO-2 trial in Renal cell carcinoma released by AVEO Oncology
- 08 May 2024 Pharmacokinetic and Pharmacodyanamic data from a preclinical trial in neovascular age-related macular degeneration released by Kyowa Kirin
- 31 Jan 2024 Phase-II clinical trials in Wet age-related macular degeneration in Australia, South Korea (Ophthalmic) (NCT06116890)